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Abstract
The International Society of Oncology Pharmacy Practitioners organized a workshop to create learning opportunities on
biosimilars in pharmacy practice on 10 October 2019. The topics that were covered included (i) the development and
testing of biosimilars, (ii) the challenges of bringing biosimilars to market, and (iii) real-world data on patient safety
and perceptions during biosimilar implementation. The development of biosimilars can take up to eight years and the
extensiveness of the process depends on several factors, such as the complexity of the production process and reg-
ulatory requirements. Compared to generic products of small-molecule drugs, there is a higher barrier to market entry
for biosimilars, explaining the small number of biosimilars in the market. Appraisal of biosimilars for inclusion in hospital
formularies is also different from the review process of originator biologics, where the former is usually institution-led
and has fewer restrictions on use. When several biosimilar products are available, factors that should be considered
besides cost are licensed indications, supply chain confidence, clinical data, and product attributes. Real-world data have
shown that biosimilars are well-tolerated and have safety data that are comparable to that of the originator product.
Oncology pharmacists from the United Kingdom, Kenya, and Canada also presented their respective experiences with
biosimilar use. Different countries at varying stages of biosimilar implementation faced distinct challenges. Nevertheless,
resources to assist biosimilar implementation can potentially be shared between different regions. International Society
of Oncology Pharmacy Practitioners is well-positioned to foster professional cooperation at an international level to
drive biosimilar implementation.
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Background
As part of the society’s efforts to create learning oppor-
tunities relating to biosimilars in pharmacy practice,
the International Society of Oncology Pharmacy
Practitioners (ISOPP) organized a four-hour workshop
during the International Symposium on Oncology
Pharmacy Practice on 10 October 2019. This document
reports on the proceedings of the workshop, sharing
key learning points and discussion themes and provid-
ing an educational resource for ISOPP members.
Welcome and introduction
The workshop was opened by Emma Foreman,
Consultant Pharmacist, The Royal Marsden National
Health Service (NHS) Foundation Trust as the chair of
the ISOPP Biosimilars Taskforce. In her opening
remarks, Emma highlighted that the workshop aimed
to provide an opportunity for ISOPP members to learn
about biosimilars, which corresponded to the objec-
tives of the Taskforce.
1Department of Pharmacy, National University of Singapore, Singapore
2Department of Pharmacy, National Cancer Centre Singapore, Singapore
3Department of Clinical Pharmacy Practice, University of California
Irvine, Irvine, CA, USA
Corresponding author:
Alexandre Chan, Department of Clinical Pharmacy Practice, University of
California Irvine, 101 Theory Dr, Irvine, CA 92697-3958, USA.
Email: a.chan@uci.edu
J Oncol Pharm Practice
2020, Vol. 26 3(Supplement) 33–39
! The Author(s) 2020
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/1078155219897959
journals.sagepub.com/home/opp
The results of two surveys carried out by the ISOPP
Biosimilars Taskforce were presented. Both surveys
were open to both ISOPP members and non-members
around the world. The first survey attempted to iden-
tify the educational needs of pharmacists on biosimi-
lars. A total of 86 responses were received. While most
respondents reported being well-informed about biosi-
milars, three key areas were highlighted as training and
education gaps: (i) the evaluation of the comparative
efficacy of biosimilars against originator products, (ii)
practical guidance on managing the switch to biosimi-
lar products, and (iii) medication safety. These topics
were chosen as the focus of this Biosimilars Workshop.
The second survey, which aimed to describe biosimilar
implementation practices around the world, received a
total of 90 responses; 74% of the respondents reported
the use of biosimilars in their institutions. Among
respondents who reported no use of biosimilars, 45%
stated that the introduction of biosimilars was being
considered. The main barriers to the use of biosimilars
included the unavailability of biosimilars, clinician
resistance, and issues with purchasing contracts or pro-
curement arrangements.
How are biosimilars developed and
tested?
Paresh Patel, Senior Biosimilar Business Development
Manager, Accord Healthcare, provided an overview of
the development pipeline of new biosimilars.
Biosimilars are defined as biological medicines that
have been shown to have no clinically meaningful dif-
ference from the originator product in terms of quality,
safety, and efficacy. Nevertheless, due to differences
in the production process, it is unlikely to produce
identical copies of the originator product. The term
“bio-better” was also briefly introduced where the
new biological product may be superior to the origina-
tor. However, “bio-betters” may be subject to different
evaluation pathways by regulatory authorities and no
clear guidance has yet been established.
The development of biosimilars, which may take up
to eight years, begins with the determination of Critical
Quality Attributes (CQAs). CQAs refer to physical,
chemical, biological, or microbiological properties
that should fall within an appropriate limit, range, or
distribution to ensure the desired product quality.1
Examples of CQAs are product potency and purity.
The determination of CQAs is a crucial step in the
developmental process as CQAs of the biosimilar
have to match those of the originator product. Once
analytical and functional assays have established that
the biosimilar is sufficiently similar to the originator
molecule, preclinical studies, phase I studies, and
phase III studies can be conducted to demonstrate
the absence of any clinically meaningful differences
from the originator product.
The comprehensiveness of the development process
hinges on several factors and increases with the com-
plexity of the originator molecule or production pro-
cess. The study design and outcomes of downstream
pre-clinical and clinical studies also depend on how
closely the biosimilar matches the originator products
in analytical and functional assays. Regulatory approv-
al requirements, such as the need for pre-clinical animal
studies, will also influence the development strategy of
biosimilars. While regulatory requirements in different
regions may differ, the developmental strategy is usu-
ally based on the most stringent requirements if the
biosimilar is planned to be marketed at a global level
to avoid delays in launching the product.
The extrapolation of biosimilars approval for other
indications of the originator product can lead to
reduced developmental cost and increased access to
the biosimilars. Nevertheless, extrapolation should be
justified based on the totality of evidence, including the
mode of action of the originator product, characteriza-
tion of the biosimilar molecule, and pharmacokinetic
and pharmacodynamic similarities between the biosi-
milar and originator product.
Simon Cheesman, Lead Hematology Pharmacist at
University College London Hospitals (UCLH),
described the evaluation of biosimilars when making
formulary decisions. The implementation process of
biosimilars is different from that of originator prod-
ucts. Compared to originator products, the introduc-
tion of biosimilars is usually institution-led, rather than
clinician-led and currently lacks clear commissioning
guidance. Biosimilars are also usually listed in the for-
mulary for a broad range of indications with fewer
restrictions on use. When introducing biosimilars, a
switching strategy for existing patients should also be
considered and planned.
Various parties may serve as the appraisal authority,
ranging from national regulatory agencies to regional
purchasing groups, each with a different set of priori-
ties to consider. It is recommended for the appraisal
process to begin 3–6months before biosimilar avail-
ability to avoid delays in the introduction and uptake
of the biosimilar product, which can lead to missed
opportunities for cost-savings (refer to the Cancer
Vanguard website2 for recommended implementation
timeline). A range of information sources can be uti-
lized in the appraisal process, such as the summary of
product characteristics, European Public Assessment
Reports, and manufacturer’s information. Clinical
trial publications are useful to provide detailed clinical
evidence to support the implementation of biosimilars.
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There may be more than one biosimilar product to
choose from. Establishing a clear criterion to differen-
tiate between different biosimilars of the same biologic
can be challenging, but all considerations should
embed the concept of selecting the “best value biolog-
ic”. There is a possibility that the originator product is
the best value biologic. Several factors that should be
considered are:
1. Market authorization:
The biosimilar selected should ideally be licensed for
the desired indications in the relevant jurisdiction.
2. Supply chain confidence:
To avoid disruption of supply, especially during the
early phases of the implementation, the manufactur-
er should ideally be a reputable biotechnology com-
pany, have sufficient manufacturing sites, have a
minimal history of shortages, and provide strong
customer support. While an important factor to con-
sider, accurate information on the reliability of sup-
pliers may be difficult to ascertain.
3. Clinical data:
Clinical data supporting the use of the biosimilar
should be drawn from studies with relevant study
populations and endpoints. Studies on biosimilar
switching will also provide useful data to guide
change to the biosimilar among existing patients.
Furthermore, pharmacovigilance data or plans for
post-marketing surveillance should be available to
collect long-term safety data for comparison against
the originator product.
4. Product attributes:
The formulation and presentation of the biosimilar
should not lead to additional barriers to adoption.
For example, the packaging should be clear and
compliant to the European Union Falsified
Medicine Directive.3 Other relevant product attrib-
utes to be scrutinized include shelf-life, storage, vial
sizes, in-use stability data, administration devices,
and excipients.
5. Price:
The price of the biosimilar should be taken into con-
sideration to maximize savings.
Several systemic or pathway barriers may hinder
the implementation of biosimilars. For example, origi-
nator biologics may have enhanced stability data,
evidence-backed rapid infusion schedules, off-label
indications, or more convenient routes of administra-
tion. Reluctance to switch to biosimilars may also stem
from the provision of funds by the pharmaceutical
industry to carry out research or healthcare services.
Case studies—Comparing experiences
of biosimilar implementation around
the world
Jatinder Harchowal, Chief Pharmacist and Clinical
Director, The Royal Marsden NHS Foundation
Trust, United Kingdom (UK), shared the experience
of UK hospitals in the implementation of the rituximab
biosimilar. When infliximab and etanercept biosimilars
were previously introduced in the UK, uptake was
shown to be inconsistent due to a lack of national
incentive or drive. The subsequent availability of a bio-
similar for rituximab, which could potentially result in
a high amount of savings for the healthcare system,
presented an opportunity to establish system-wide
changes to improve biosimilar uptake and design stra-
tegic pathways for future biosimilar implementation.
The implementation project was carried out across
three hospital systems—The Royal Marsden, UCLH,
and The Christie Hospitals—with Sandoz collaborat-
ing in a non-commercial capacity. Key stakeholders in
the implementation process, including clinicians, phar-
macy personnel, patients, and professional groups,
were engaged. Education sessions were conducted for
healthcare professionals to improve their understand-
ing and confidence in the use of biosimilars. Patient
education resources were also developed jointly with
patient groups such as the Lymphoma Association.
To assist in biosimilar implementation at an institu-
tional level, policies were also developed for local
NHS trusts with institutional approval.
Among the most critical steps in biosimilar imple-
mentation was the development of a central repository
of information relevant to the introduction of the
rituximab biosimilar. This repository was hosted on
the Cancer Vanguard website2 to provide accessible
resources across the UK, which could be easily adapted
for use in local settings. Examples of resources found
on the Cancer Vanguard website included the process
timeline for biosimilar adoption, guidance documents
for biosimilar implementation, and education materials
for healthcare professionals and patients.
At The Royal Marsden and UCLH, the switch to
the rituximab biosimilar occurred in July 2017. Eligible
patients were also assigned to rapid rituximab infusions
as per protocol. Only grades 1 and 2 infusion reactions
were reported, at rates comparable to the originator
product. No practical problems were observed during
the implementation phase. Learning from this experi-
ence, similar strategies were adopted in the implemen-
tation of trastuzumab and adalimumab biosimilars,
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resulting in even higher uptake rates of the biosimilar
products.
Nevertheless, the implementation of biosimilars
should also take into account the patient experience.
Using rituximab as an example, patients who were on
single-agent rituximab regimens remained on the origi-
nator product formulated for subcutaneous administra-
tion to avoid unnecessary intravenous infusions, even
after the biosimilar was introduced.
Winnie Mwangi, Oncology and Clinical Pharmacist,
Meru Teaching and Referral Hospital, Kenya, provid-
ed the Kenyan perspective on biosimilars. In Kenya,
cost is a key consideration. As the national health
insurance coverage is usually inadequate for oncology
patients, substantial out-of-pocket expenditure can
impose a financial burden on impoverished patients.
Therefore, the affordability of treatment is an impor-
tant consideration. Consequently, biologics with first-
line indications are often used as second- or third-line
treatments and patients may not be able to complete all
treatment cycles required.
In Kenya, biosimilars are not supplied by the
national procurement agency that distributes medica-
tions to all public healthcare facilities. Purchase of bio-
similars at the hospital level is allowed but rarely occurs
due to stringent procurement guidelines. As a result,
biosimilar uptake rates are low at approximately 20%
in public hospitals. The usage of biosimilars is possibly
higher in private hospitals.
Currently, there are no clear guidelines in Kenya on
the implementation of biosimilars. While regulatory
guidelines are available for the registration of biosimi-
lars, biomimics (replica medicines of biotherapeutic
products that do not meet regulatory requirements of
biosimilarity to the originator product4) are introduced
to the Kenyan market via special import permits or
parallel imports and are assumed to be equivalent to
biosimilars. Due to resource constraints, biomimics are
often the only treatment option available to patients.
As such, the role of biomimics is being heavily dis-
cussed in Kenya.
Clinicians and healthcare workers treat biosimilars
similar to generics. Biologics are prescribed using the
International Nonproprietary Name without specifica-
tion of the brand name while automatic substitution
of originator products with biosimilars, or even biomi-
mics, is routinely carried out based on costs and avail-
ability at the discretion of the pharmacist. Moving
forward, a crucial gap to address would be the educa-
tion of healthcare professionals on what biosimilars
are, and biosimilar switching. There is also a critical
need to enforce existing regulations on biosimilars
and establish guidelines on biosimilar implementation.
Glenn Myers, Clinical Pharmacist, The Moncton
Hospital, Moncton, Canada, talked about the state of
biosimilar implementation in Canada. Compared to
the UK, biosimilars are relatively new in Canada
with Grastofil–filgrastim being the first biosimilar to
be approved for use in 2018. An evaluation pathway
for biosimilars remains to be established.
Health Canada is the agency responsible for regula-
tory review and approval of drugs in Canada. Once
approved, oncology drugs undergo health technology
assessment by the pan-Canadian Oncology Drug
Review (pCODR) Expert Review Committee, which
provides recommendations on drug reimbursement.
However, the pCODR Expert Review Committee
does not evaluate biosimilars, but instead, a rapid
response team established by pCODR reviews evidence
on biosimilar switching and interchangeability between
biosimilars and originator biologics. The team also
provides input to supplement price negotiation for
group purchasing.
To ensure appropriate implementation and cost-
effective use of therapeutic oncology biosimilars across
Canada, the pan-Canadian Oncology Biosimilar
Initiative (pCOBI) was established. The main focus of
pCOBI is on the development of educational materials
and implementation guidelines. Clinical guidance, reim-
bursement, evaluation, and reinvestment of savings
serve as secondary priority areas.
Lessons that were extrapolated from the introduc-
tion of Grastofil–filgrastim include:
1. Greater transparency on approval date to ensure
that front-line healthcare professionals are ade-
quately prepared for biosimilar implementation.
2. Clearer guidance for biosimilar switching.
3. More education for healthcare professionals to cor-
rect misperceptions, such as biosimilars being asso-
ciated with higher adverse event rates, and improve
uptake.
4. Streamlining of inpatient and outpatient access to
biosimilars.
During the panel discussion, it was emphasized that
biosimilar uptake around the world has been inconsis-
tent despite the potential savings associated with
biosimilar use. International collaboration is crucial
to promote the use of biosimilars. Implementation
pathways and resources developed by countries with
experience in biosimilar implementation can be success-
fully adapted for use in other settings. Canada, for
instance, has benefitted from tools and resources pro-
vided by the Cancer Vanguard project in the UK. This
example highlights the importance of sharing informa-
tion and experience on biosimilar implementation at an
international level.
However, different countries are at different stages
in the trajectory of biosimilar implementation and thus,
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face different barriers in the introduction of biosimi-
lars. For example, Kenya, Nigeria, and other African
countries have erratic drug distribution channels and
lack confidence in the quality of biosimilars/biomimics
that are available in the region. To resolve this concern,
regional collaboration between healthcare professio-
nals, led by professional organizations, can help to
convince policymakers of the importance of biosimilars
in generating savings for the healthcare system and the
need for clear implementation guidance. Furthermore,
national or regional supply chains need to be set up
to procure products approved by regulatory agencies,
such as the United States Food and Drug
Administration or European Medicines Agency, to
ensure consistency in the quality of biosimilars pro-
cured. Other countries that have initiated but are in
the early phases of biosimilar implementation may be
more concerned with issues related to educating
patients and healthcare professionals as well as han-
dling biosimilar shortages.
Challenges of bringing biosimilars
to market
Enrico Bovi, UK Oncology Biosimilars Director,
Pfizer, discussed the importance and challenges of
bringing biosimilars to the market. Compared to
launching a generic version of a small-molecule drug,
the process of marketing a biosimilar is more complex
and poses more risks to the pharmaceutical company.
Proof of quality and pharmacokinetic bioequivalence is
usually sufficient to demonstrate equivalence to the
originator product for new generics. However, new bio-
similars also require data on molecular similarity and
clinical data on efficacy and safety. This higher barrier
to market entry explains the low average number of
biosimilars for biological medicines in the market in
contrast to the large number of generics for small-
molecule drugs.
Nevertheless, it is important for the pharmaceutical
industry to invest in biosimilars as they allow quicker
and wider patient access to biologics at more afford-
able prices. Furthermore, the acceptance of biosimilars
has been increasing. Pharmaceutical companies also
have well-established production facilities that can
ensure a reliable and affordable supply of biosimilars.
Biosimilars uptake has grown in the UK with
increasing price erosion as more biosimilars are
launched. This trend has shaped a positive landscape
in the UK for biosimilar manufacturers. The commis-
sioning framework for biological medicines published
by the NHS aims for 90% of treatment-naı¨ve patients
and 80% of existing patients to be prescribed the “best
value biologic” within 3 and 12months of biosimilar
launch,5 respectively. Existing data show that the speed
of biosimilar uptake has increased from 2015 to 2018,
driven by price erosion and well-established implemen-
tation pathways.
As more biosimilars are introduced, further price
erosion may threaten the market sustainability of bio-
similars. Pharmaceutical companies should consider
targeting a sustainable price and providing valuable
services rather than charging a higher price while cor-
nering the market to recoup costs within a short
amount of time.
In addition to providing more affordable access to
biologics, biosimilar manufacturers should also consid-
er crucial issues such as maintaining a reliable supply
chain, as switching between different biosimilars is dif-
ficult and complex. Biosimilar companies should also
provide reliable stability data and aim for reasonable
and convenient storage conditions. Unmet needs that
biosimilar manufacturers should consider tackling in
the future include simplifying intravenous infusion pro-
cesses and evaluating the possibility of homecare
delivery.
Administration and patient safety
Geoff Saunders, Consultant Pharmacist, The Christie
Hospital, UK, presented data on patient safety and
perceptions during the implementation of a trastuzu-
mab biosimilar. Real-world data on patient safety and
perception is crucial to improve the acceptance of bio-
similars among clinicians. A pharmacovigilance audit
was carried out by The Christie Hospital, UK, to doc-
ument adverse drug reaction (ADR) rates of a trastu-
zumab biosimilar during the first six months of
biosimilar implementation. Any adverse event that
occurred within 48 h of biosimilar administration was
documented. Out of the 1000 trastuzumab doses that
were administered over six months, a total of 25 ADRs
were documented with only eight attributable to the
trastuzumab biosimilar (Table 1). All related ADRs
were known side effects of trastuzumab, and occurred
at rates comparable to the originator product.
Table 1. ADRs attributable to trastuzumab biosimilar during
pharmacovigilance audit.
ADR
Number
of cases
Treatment
cycles
Infusion reaction 5 Cycle 1
(all trastuzumab-naı¨ve
patients)
Injection site pain 1 Cycle 9
Extravasation 1 Cycle 12
Heart failure 1 Cycle 20
ADR: adverse drug reaction.
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The audit results increased the confidence of clinicians
to switch to biosimilars.
Data on patient perceptions were also collected
during the introduction of the trastuzumab biosimilar.
While the majority of the patients did not recall any
discussion about biosimilars, those who did were able
to demonstrate a good understanding of biosimilars.
Most patients did not have further questions on bio-
similars but wanted reassurance that biosimilars were
as effective as the originator biologics. These observa-
tions indicate that drug efficacy remains the main
priority of patients regardless of which product is
used. Furthermore, patients also overwhelmingly
agreed that it was important that the use of biosimilars
would allow the reallocation of NHS resources for
newer cancer treatments.
The use of rapid infusion protocols allows
patients to receive biologics at an accelerated rate
after tolerating the initial cycle with no infusion reac-
tions. To reduce chair time, The Christie Hospital
aimed to continue the use of rapid infusion protocols
with biosimilars, where only treatment-naı¨ve patients
will be offered prolonged infusions at conventional
rates and extended monitoring time. During the imple-
mentation of the trastuzumab biosimilar, none of the
patients who transited from the originator product
experienced infusion reactions. In the case of rituxi-
mab, only one patient developed tachycardia after
switching from the originator product to a biosimilar.
Data from both the trastuzumab and rituximab expe-
rience show that the rapid infusion protocols can be
safely used to administer biosimilars without the need
to re-challenge patients at conventional infusion rates.
A rapid infusion protocol for bevacizumab has also
recently been published.6 Anticipating the launch of a
new bevacizumab biosimilar, the current discussion
revolves around the timing of rapid infusion protocol
implementation—whether it should be implemented
immediately whilst still using the originator product
or after the switch to biosimilars has been completed.
Confusion between the originator product and the
biosimilar may occur during prescribing, dispensing, or
ADR reporting during the early stages of biosimilar
implementation. These potential errors may be avoided
by keeping only the biosimilar product in the invento-
ry. If electronic systems are involved, only the biosimi-
lar option should be retained. Keeping both the
originator biologic and the biosimilar is unnecessary
since equivalence has been demonstrated between the
two products and may lead to medication errors or
introduce unnecessary complexity in operating proce-
dures. Exceptions may arise if the biosimilar is not
licensed for all indications or routes of administration
of the originator biologic.
Emerging issues
Reinvestment of savings from biosimilars
Savings from the use of biosimilars can be reinvested
in new cancer treatments, such as chimeric antigen
receptor (CAR) T-cell therapy or to expand biologics
access to more patients. Quantifying and publicizing
these outcomes will be helpful to demonstrate to the
public the importance of implementing biosimilars.
Patients who have switched to biosimilars will also under-
stand how they have helped to reduce the financial
burden imposed on the healthcare system, possibly lead-
ing to patient empowerment.
Private hospitals
Private care providers also face challenges in biosimilar
implementation. Private practitioners value their
autonomy in prescribing and often prefer originator
products. Pharmaceutical companies also do not
engage private providers in implementation projects
due to low volumes of biosimilar sales.
However, experience with clinicians who manage
private patients has been favorable in public hospitals,
where education and training have helped to drive
acceptance of biosimilars among both clinicians and
patients. Establishing clear and consistent guidance in
the selection and approval of formulary items may help
private providers in introducing and increasing the
usage of biosimilars.
Re-evaluation
The lower prices conferred by biosimilars provide an
opportunity to review the economic appraisal of biolog-
ics previously found to be not cost-effective, possibly
leading to the re-evaluation of the role of biologics in
therapy. This re-evaluation is especially important with
the emergence of new but more expensive treatments.
For example, the economic evaluation of bevacizumab
in ovarian cancer should be reviewed with the launch of
a more affordable biosimilar, especially as poly(ADP-
ribose) polymerase (PARP) inhibitors have emerged as
new but costly treatment options.
Summary
Biosimilar implementation will lead to a significant
amount of savings in the healthcare system.
Nevertheless, biosimilar uptake remains inconsistent
around the world. Collaborations between different
countries and industry partners are pivotal in driving
biosimilar implementation through the sharing of expe-
rience and readily accessible resources. Engagement of
stakeholders, including patients, and education of
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patients and healthcare professionals have been shown
to be critical steps in the process. To further improve
biosimilar implementation, data on patient outcomes
and experience should also be collected to refine the
process and convince health systems that biosimilars
and originator products are clinically equivalent.
Harnessing the collaborative power of pharmacists
from different countries and its role as an international
professional organization, ISOPP is well-positioned to
assist in the distribution of information and resources
to lobby for and drive biosimilar implementation.
Efforts include the publication of a position statement
and the dissemination of a biosimilar education toolkit.
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